ZimVie (NASDAQ:ZIMV), Inc. is a global medical technology company that emerged as an independent, publicly traded entity in July 2023 following a spin-off from Zimmer Biomet. Headquartered in the United States, ZimVie focuses on advancing patient care through a comprehensive portfolio of spine and dental solutions. The company leverages decades of research and development in orthopedics and dental care to deliver clinically proven products and technologies.
In its spinal business, ZimVie designs and manufactures implants, instruments and biologics for use in minimally invasive procedures, motion-preserving therapies and complex reconstructions. Its product offerings include interbody devices, cervical and thoracolumbar systems, and bone graft substitutes aimed at improving fusion outcomes and patient recovery. ZimVie’s dental division develops endosseous implants, prosthetic components, digital workflow tools and regenerative materials intended to restore function and aesthetics in dental surgery.
ZimVie serves healthcare providers across North America, Europe, Asia-Pacific and select emerging markets. The company operates research and manufacturing facilities in the United States and Europe, as well as distribution centers that support its global reach. By combining the legacy expertise of Zimmer Biomet’s spine and dental units with focused investments in innovation, ZimVie seeks to address unmet clinical needs and expand access to advanced care.
Since its establishment as a standalone company, ZimVie has prioritized strategic partnerships and ongoing product development to enhance its technology platforms. The company’s management team draws on extensive experience in medical device commercialization, regulatory affairs and clinical research. Through a commitment to quality, training and customer support, ZimVie aims to empower surgeons and clinicians with solutions that improve patient outcomes and quality of life.
